Can immunotherapy before surgery stop early oral cancer from returning?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed primary squamous cell carcinoma of the oral cavity. 2. Clinical stage cT2N0M0 according to the AJCC 8th edition staging system. 3. Age between 18 and 75 years old. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Deemed eligible for radical surgical resection of the primary tumor and regional lymph nodes. 6. Adequate organ function within 14 days prior to randomization: * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L * Platelets \>= 100 x 10\^9/L * Hemoglobin \>= 9.0 g/dL * Total bilirubin \<= 1.5 x upper limit of normal (ULN) * AST and ALT \<= 2.5 x ULN * Serum creatinine \<= 1.5 x ULN or creatinine clearance \>= 50 mL/min 7. Voluntary written informed consent provided by the patient or legal representative. Exclusion Criteria: 1. Presence of regional lymph node metastasis or distant metastasis (cN+ or M1). 2. Prior systemic antitumor therapy, radiotherapy, or immunotherapy for head and neck cancer. 3. History of other active malignant neoplasms within the past 5 years (except adequately treated non-melanoma skin cancer or carcinoma in situ). 4. Active autoimmune disease or history of severe autoimmune disease requiring systemic corticosteroids or immunosuppressive agents. 5. Severe cardiovascular disease, including unstable angina, myocardial infarction within 6 months, or uncontrolled heart failure (NYHA Class III/IV). 6. Active infection requiring systemic intravenous antimicrobial treatment. 7. Known history of severe allergy or hypersensitivity to sintilimab, albumin-bound paclitaxel, carboplatin, or their excipients. 8. Pregnant or breastfeeding women, or patients of childbearing potential unwilling to use effective contraception during the study and for 6 months after the last dose. 9. Any underlying medical condition or psychiatric disorder that, in the opinion of the investigator, would jeopardize participant safety or trial compliance.